Anti-CDw17 (Lactosylceramide or LacCer) Monoclonal Antibody(Clone: HO18.3G-6.F5)
Roll over image to zoom in
Shipping Info:
For estimated delivery dates, please contact us at support@abeomics.com
| Amount : | 100 µg |
| Isotype : | Mouse IgM, kappa |
| Content : | 200 µg/ml of Ab Purified from Bioreactor Concentrate. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml. |
| Storage condition : | Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. |
| Alternative Name : | Lactosylceramide; LacCer; β-D-galactosyl-(1-4)-β-D-glucosyl-(1-1')-ceramide;CDw17 |
| Immunogen Information : | β-2 Microglobulin associated proteins from a detergent lysate of human PBL |
CD17 is an intermediate glycosphingolipid from the metabolism of higher gangliosides that localizes to sphingolipid-sterol rafts. CD17 is detectable in monocytes, granulocytes, basophils, platelets, a subset of peripheral B cells (CD19+) and tonsil dendritic cells. It is rapidly down regulated on activated granulocytes and is upregulated on IL-2 activated T lymphocytes. CD17 binds to bacteria and may function in phagocytosis. VEGF-treated endothelial cells can produce CD17, which can then mediate signaling toward PECAM-1 expression and angiogenesis. Tumor necrosis factor )-induced astrogliosis (astrocyte proliferation and glial fibrillary acidic protein (GFAP) upregulation) in response to neuro-inflammation (i.e. spinal cord injury) causes an increase in intracellular levels of CD17. Aberrant levels of glycosphingolipids are a feature of cancer cells and may influence integrin clustering and internalization.
Flow Cytometry (0.5-1µg/million cells); Immunofluorescence (0.5-1µg/ml); Optimal dilution for a specific application should be determined.
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
|
There are currently no product reviews
|
